Bacil Pharma board of directors concluded its meeting on August 29, 2026, approving the director’s report for FY26 and fixing the date for its 39th annual general meeting. The session also saw significant changes in leadership designations and a proposal to increase authorized share capital.

The company’s 39th AGM is scheduled for September 23, 2026, at 3:00 pm. The meeting will be held through video conferencing or other audio-visual means, in compliance with Ministry of Corporate Affairs and SEBI circulars. The register of members and share transfer books will remain closed from September 17 to September 23, 2026. Notably, the company has not declared any dividend for the financial year 2025-2026.

Board Meeting Outcomes

The board approved several key resolutions during the meeting, which commenced at 12:05 pm and concluded at 1:00 pm. The primary focus was on corporate governance matters and structural adjustments to the company’s capital base.

Leadership Changes

A notable development from the meeting is the proposed change in designation of Chaitali Kalpataru Shah. The board seeks shareholder approval to elevate her role from Executive Director to Managing Director, effective August 25, 2026. This change requires a special resolution at the upcoming AGM.

Additionally, the board appointed two new directors on August 25, 2026: Anil Singh as Non-Executive Director and Mahesh Singh as Non-Executive Independent Director. Their appointments are subject to regularization by shareholders at the AGM. The board also seeks re-appointment of Omprakash Pyarelal Sonar and Vivek Mukesh Yadav as Non-Executive Independent Directors.

Capital Structure Adjustment

The company proposes to increase its authorized share capital from ₹20 crore (2 crore equity shares) to ₹70 crore (7 crore equity shares). Each share has a face value of ₹10. The new shares will rank pari passu with existing equity shares. This move aims to broaden the capital structure and meet future funding requirements.

Auditor Appointment

The board recommends the appointment of M/s Sarang Shivajirao Chavan & Associates Chartered Accountants as statutory auditors. If approved, they will hold office from the conclusion of the 39th AGM until the conclusion of the 43rd AGM. This replaces the previous auditors, Laxmikant Kabra & Co LLP, who resigned in August 2025.

Chaitali Kalpataru Shah, Director and CFO, signed the notification issued to the Bombay Stock Exchange listing department.

Bacil Pharma Limited appointed Mahesh Singh as an additional independent director and Anil Shiv Charan Singh as an additional non-executive director on August 25, 2026. The appointments require shareholder approval.

The board approved the appointments during a meeting held on Tuesday, August 25, 2026. Both directors have submitted necessary declarations under the Companies Act, 2013 and SEBI LODR Regulations. They are not debarred from holding office by any regulatory authority.

Director Profiles

Mahesh Singh brings over seven years of experience in the trading industry. His expertise includes product sales, brand establishment, and online sales strategies. The company cited his experience in accounting and financial matters as the reason for his appointment.

Anil Shiv Charan Singh has experience in business management and commercial activities. His background includes commodity trading and related business operations. The board noted his business acumen would contribute to strategic decision-making.

Regulatory Compliance

The appointments comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Detailed disclosures are enclosed in Annexure A of the filing. Neither director is related to any existing director of the company.